It began typically enough: the Supreme Court denied cert in Athena, Chargepoint and Trading Technologies; Brexit finally happened; the Federal Circuit refused to rehear Arthrex; and the IP community was waiting for important rulings in copyright cases like Google v. Oracle and trademark cases like Booking.com. But then came COVID. Courts and offices shut down, the USPTO went almost 100% remote, and all conferences and events were cancelled into 2021. At the same time, pharmaceuticals, vaccines – and the IP around them – became the only thing on anyone’s mind.
Recent Posts
- CAFC Gives Centripetal Another Shot at PTAB in Case Tied to APJ’s Alleged Bias
- Undermining Innovation: The Consequences of Closing the Rocky Mountain Regional USPTO Office
- Does the 2025 Version of PERA Indirectly Sanction Judicially Created, Non-Statutory ODP?
- Squires Takes Over All IPR Institution Decisions in Memo to PTAB Judges
- Other Barks & Bites for Friday, October 17: CAFC Finds Prosecution Disclaimer in Examiner Acceptance of Patentee’s Scope; Japan Urges Opt-In Copyright Model for Sora 2; and Seventh Circuit Clarifies Evidence Required for Sound Recording Copyright Claims